Cellular and molecular biology of membranous nephropathy

Journal of Nephrology

Volumn 19, Issue 6, 2006, Pages 699-705

  Couser, William G ^a,c   Nangaku, Masaomi ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE   (United States)

Author keywords

Complement; Membranous nephropathy; MN; Nephritis; Nephrotic syndrome; Podocyte

Indexed keywords

COMPLEMENT COMPONENT C5B; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH FACTOR; OXIDIZING AGENT; PROSTANOID; PROTEINASE; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HYPERTROPHY; IMMUNE COMPLEX DEPOSITION; IMMUNOPATHOLOGY; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PROTEINURIA; REVIEW; UPREGULATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; APOPTOSIS; AUTOANTIBODIES; CELL CYCLE; COMPLEMENT MEMBRANE ATTACK COMPLEX; GENE EXPRESSION REGULATION; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; PODOCYTES; RATS;

EID: 33947226955     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-15.
2. Hirayama K, Ebihara I, Yamamoto S, Kai H, Muro K, Yamagata K, Kobayashi M, Koyama A. Predominance of type-2 Immune response in idiopathic membranous nephropathy. Nephron 2002; 91: 255-61.
3. Masutani K, Taniguchi M, Nakashima H, Yotsueda H, Kudoh Y, Tsuruya K, Tokumoto M, Fukuda K, Kanai H, Hirakata H, Iida M. Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy. Nephrol Dial Transplant 2004; 19: 580-6.
4. Kawasaki Y, Suzuki J, Sakai N, Isome M, Nozawa R, Tanji M, Suzuki H. Evaluation of T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis. Am J Kidney Dis 2004; 44: 42-9.
5. Heymann W, Lund HZ, Hackel DB. The nephrotic syndrome in the rats; with special reference to the progression of the glomerular lesion and to the use of nephrotoxic sera obtained from ducks. J Lab Clin Med 1952; 39: 218-24.
6. Couser WG, Steinmuller DR, Stilmant NM, Salant DJ, Lowenstein LM. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 1978; 62: 1275-87.
7. van Damme BJC, Fleuren GJ, Bakker WW, Vernier RL, Hoedemaeker PhJ. Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens: Part V: fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis. Lab Invest 1978; 38: 502-10.
8. Kerjaschki D, Farquhar MG. Immunochemical localization of the Heymann nephritis antigen (gp330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 1983; 157: 667-86.
9. Neale TJ, Wilson CB. Glomerular antigens in Heymann's nephritis: reactivity of eluted and circulating antibody. J Immunol 1982; 128: 323-30.
10. Madaio MP, Salant DJ, Cohen AJ, Adler S, Couser WG. Comparative study of in situ immune deposit formation in active and passive Heymann nephritis. Kidney Int 1983; 23: 498-505.
11. Couser WG, Salant DJ. In situ immune complex formation and glomerular injury. Kidney Int 1980; 17: 1-13.
12. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982; 79: 5557-61.
13. Farquhar M, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6: 35-47.
14. Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56: 355-77.
15. Horl WH, Kerjaschki D. Membranous glomerulonephritis (MGN). J Nephrol 2000; 113: 291-316.
16. Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1214-22.
17. Salant DJ, Belok S, Madaio MP, Couser WG. A new role for complement in experimental membranous nephropathy in rats. J Clin Invest 1980; 66: 1339-50.
18. Perkinson DT, Baker PJ, Couser WG, Johnson RJ, Adler S. Membrane attack complex deposition in experimental glomerular injury. Am J Pathol 1985; 120: 121-8.
19. Baker PJ, Ochi RF, Schulze M, Johnson RJ, Campbell C, Couser WG. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 1989; 135: 185-94.
20. Cybulsky AV, Quigg RJ, Salant DJ. The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy. J Immunol 1986; 137: 1511-6.
21. Savin VJ, Johnson RJ, Couser WG. C5b-9 increases albumin permeability of isolated glomeruli in vitro. Kidney Int 1994; 46: 382-7.
22. Walport M. Advances in immunology: complement - first of two parts. N Engl J Med 2001; 344: 1058-66.
23. Kerjaschki D, Schulze M, Binder S, Kain R, Ojha PP, Susani M, Horvat R, Baker PJ, Couser WG. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989; 143: 546-52.
24. Couser WG, Baker PJ, Adler S. Complement and the direct mediation of immune glomerular injury. Kidney Int 1985; 28: 879-900.
25. Alpers CE, Couser WG. Membranous nephropathy. In Couser WG, Neilson EG (Eds). Immunologic renal diseases (2nd edn). Philadelphia: Lippincott Williams and Wilkins 2001; 1029-55.
26. Schulze M, Pruchno CJ, Burns M, Baker PJ, Johnson RJ, Couser WG. Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis. Am J Pathol 1993; 142: 179-87.
27. Cattran DC, Pandes M, Reich HN, Scholey J, Miller J. Does complement deposition correlate with presenting clinical features and/or outcome in idiopathic membranous nephropathy [abstract]. J Am Soc Nephrol 2002; 13: 450.
28. Schulze M, Baker PJ, Perkinson DT, Johnson RJ, Ochi RF, Stahl RA, Couser WG. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 1989; 35: 60-8.
29. Brenchley PE, Coupes B, Short CD, O'Donoghue DJ, Ballardie FW, Mallick NP. Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy. Kidney Int 1993; 41: 933-7.
30. Coupes BM, Kon SP, Brenchley PE, Short CD, Mallick NP. The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy. Nephrol Dial Transplant 1993; 8: 397-401.
31. Matsuo S, Morita Y, Yuzawa Y, Maruyama S. Urinary membrane attack complex (MAC) is a potent predictor of poor renal outcome in proteinuric glomerular diseases. J Am Soc Nephrol 2004; 15: 328A.
32. Petermann AT, Krofft R, Blonski M, Hiromura K, Vaughn M, Pichler R, Griffin S, Wada T, Pippin J, Durvasula R, Shankland SJ. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 2003; 64: 1222-31.
33. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1195-204.
34. Fosbrink M, Niculescu F, Rus H. The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res 2005; 31: 37-46.
35. Adler S, Baker PJ, Johnson RJ, Ochi RF, Pritzl P, Couser WG. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 1986; 77: 762-7.
36. Torbohm I, Schonermark M, Wingen AM, Berger B, Rother K, Hansch GM. C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. Kidney Int 1990; 37 1098-104.
37. Neale TJ, Ullrich R, Ojha P, Poczewski H, Verhoeven AJ, Kerjaschki D. Reactive oxygen species and neutrophil respiratory burst cytochrome b558 are produced by kidney glomerular cells in passive Heymann nephritis. Proc Natl Acad Sci U S A 1993; 90: 3645-9.
38. Shah SV. Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol Renal Fluid Electrolyte Physiol 1988; 254: F337-44.
39. Peng H, Takano T, Papillon J, Bijian K, Khadir A, Cybulsky AV. Complement activates the c-Jun N-terminal kinase/stress-activated protein kinase in glomerular epithelial cells. J Immunol 2002; 169: 2594-601.
40. Kerjaschki D, Neale TJ. Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 1996; 7: 2518-26.
41. Lotan D, Kaplan BS, Fong JS, Goodyer PR, de Chadarevian JP. Reduction of protein excretion by dimethyl sulfoxide in rats with passive Heymann nephritis. Kidney Int 1984; 25: 778-88.
42. Kaplan BS, Milner LS, Lotan D, Mills M, Goodyer PR, Fong JS. Interactions of dimethyl sulfoxide and nonsteroidal anti-inflammatory agents in passive Heymann's nephritis. J Lab Clin Med 1986; 107: 425-30.
43. Haas M, Mayer G, Wirnsberger G, Holzer H, Ratschek M, Neyer U, Neuweiler J, Kramar R, Schneider B, Breiteneder-Geleff S, Regele HM, Horl WH, Kerjaschki D. Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. Wien Klin Wochenschr 2002; 114: 143-7.
44. Cai Y, Beziau A, Sich M, Kleppel MM, Gubler MC. Collagen distribution in human membranous glomerulonephritis. Pediatr Nephrol 1996; 10: 14-21.
45. Kim Y, Butkowski R, Burke B, Kleppel MM, Crosson J, Katz A, Michael AF. Differential expression of basement membrane collagen in membranous nephropathy. Am J Pathol 1991; 139: 1381-8.
46. Minto AW, Kalluri R, Togawa M, Bergijk EC, Killen PD, Salant DJ. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy. Proc Assoc Am Physicians 1998; 110: 207-17.
47. Minto AW, Fogel MA, Natori Y, O'Meara YM, Abrahamson DR, Smith B, Salant DJ. Expression of type I collagen mRNA in glomeruli of rats with passive Heymann nephritis. Kidney Int 1993; 43: 121-7.
48. McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 1996; 97: 1094-101.
49. Watanabe K, Kinoshita S, Nakagawa H. Gelatinase secretion by glomerular epithelial cells. Nephron 1990; 56: 405-9.
50. Shankland SJ, Pippin J, Pichler RH, Gordon KL, Friedman S, Gold LI, Johnson RJ, Couser WG. Differential expression of transforming growth factor-beta isoforms and receptors in experimental membranous nephropathy. Kidney Int 1996; 50: 116-24.
51. Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, Kershaw D, Wiggins R. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60: 957-68.
52. Sanwal V, Pandya M, Bhaskaran M, Franki N, Reddy H, Ding G, Kapasi A, Valderrama E, Singhal PC. Puromycin aminonucleoside induces glomerular epithelial cell apoptosis. Exp Mol Pathol 2001; 70: 54-64.
53. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Bottinger EP. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001; 108: 807-16.
54. Schiffer M, Mundel P, Shaw AS, Bottinger EP. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004; 279: 37004-12.
55. Ding G, Reddy K, Kapasi AA, Franki N, Gibbons N, Kasinath BS, Singhal PC. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283: F173-80.
56. Honkanen E, von Willebrand E, Koskinen P, Teppo AM, Tornroth T, Ruutu M, Gronhagen-Riska C. Decreased expression of vascular endothelial growth factor in idiopathic membranous glomerulonephritis: relationships to clinical course. Am J Kidney Dis 2003; 42: 1139-48.
57. Foster RR, Saleem MA, Mathieson PW, Bates DO, Harper SJ. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am J Physiol Renal Physiol 2005; 288: F48-57.
58. Foster RR, Hole R, Anderson K, Satchell SC, Coward RJ, Mathieson PW, Gillatt DA, Saleem MA, Bates DO, Harper SJ. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 2003; 284: F1263-73.
59. Schneeberger EE, Leber PD, Karnovsky MJ, McCluskey RT. Altered functional properties of the renal glomerulus in autologous immune complex nephritis: an ultrastructural tracer study. J Exp Med 1974; 139: 1283-302.
60. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000; 20: 175-9.
61. Kriz W, Hahnel B, Rosener S, Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995; 48: 1435-50.
62. Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG. Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. Kidney Int 1997; 52: 404-13.
63. Kim YG, Alpers CE, Brugarolas J, Johnson RJ, Couser WG, Shankland SJ. The cyclin kinase inhibitor p21Cip1/Waf1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis. Kidney Int 1999; 55: 2349-61.
64. Petermann A, Hiromura K, Pippin J, Blonski M, Couser WG, Kopp J, Mundel P, Shankland SJ. Differential expression of d-type cyclins in podocytes in vitro and in vivo. Am J Pathol 2004; 164: 1417-24.
65. Petermann A, Pippin J, Hiromura K, Monkawa T, Durvasula R, Couser WG, Kopp J, Shankland SJ. Mitotic cell cycle proteins increase in podocyte despite lack of proliferation. Kidney Int 2003; 63: 113-22.
66. Shankland SJ, Pippin J, Couser WG. Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 1999; 56: 538-48.
67. Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ. DNA damage is a novel response to sublyric complement C5b-9-induced injury in podocytes. J Clin Invest 2003; 111: 877-85.
68. Topham PS, Haydar SA, Kuphal R, Lightfoot JD, Salant DJ. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 1999; 55: 1763-75.
69. Yuan H, Takeuchi E, Taylor GA, McLaughlin M, Brown D, Salant DJ. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13: 946-56.
70. Saran AM, Yuan H, Takeuchi E, McLaughlin M, Salant DJ. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003; 64: 2072-8.
71. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, Reponen P, Tryggvason K, Camussi G. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158: 1723-31.
72. Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Paul LC, Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14: 2063-71.
73. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, Reponen P, Tryggvason K, Camussi G. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol 2001; 158: 1723-31.
74. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephol 2003; 14 (7 Suppl 2): S186-9.
75. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339: 1448-56.
76. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998; 54: 1419-28.
77. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999; 10: 2323-31.
78. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in rat with remnant kidneys. J Am Soc Nephrol 2002; 13: 928-36.
79. Rangan GK, Pippin JW, Couser WG. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerular sclerosis. Kidney Int 2004; 66: 1838-48.
80. Kaplan M. Eculizamab (Alexion). Curr Opin Investig Drugs 2002; 3: 1017-23.